Digestive Health
Benaroya Research Institute and Virginia Mason Medical Center conduct clinical trials to improve digestive health. The Center for Digestive Health at the Virginia Mason Medical Center is internationally known for bringing together experts to optimize care through innovations in research, education and a multidisciplinary approach to the treatment of digestive diseases.
Clinical Research Studies in Digestive Health
We have ongoing clinical research studies in several areas of digestive health. Studies labeled as “Enrolling” are actively recruiting new participants while studies labeled as “Closed to Enrollment” are still active but no longer seeking new participants.
Please email Digestive Health Research or call (206) 341-1021 for more information.
- Biliary and Liver Disease
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF RIFAXIMIN SOLUBLE SOLID DISPERSION (SSD) TABLETS FOR THE DELAY OF ENCEPHALOPATHY DECOMPENSATION IN CIRRHOSIS (RED-C)
Principal Investigator: Blaire Burman, MD
Status: Closed to Enrollment- Clostridioides difficile (C. diff)
-
Principal Investigator: Gautam Mankaney, MD
Status: Enrolling - Crohn's Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Completed the Studies M14-431 or M14-433
Principal Investigator: Tim Zisman, MD
Status: Closed to EnrollmentA Phase 2, Multicenter, Open-Label Extension (OLE) Study to Observe the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Subjects with Crohn's Disease
Principal Investigator: Tim Zisman, MD
Status: Closed to EnrollmentA Phase 2b Randomized, Double-blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn’s Disease
Principal Investigator: Tim Zisman, MD
Status: Closed to EnrollmentA Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Crohn's Disease
Principal Investigator: Tim Zisman, MD
Status: Closed to EnrollmentCrohn's Disease: Risankizumab versus Ustekinumab for Subjects with Crohn's Disease
Principal Investigator: Tim Zisman, MD
Status: Closed to Enrollment- Diverticulitis
Protocol for the Comparison of Surgery and Medicine on the Impact of Diverticulitis (COSMID) Trial
Principal Investigator: Val Simianu, MD
Status: Enrolling- Familial Adenomatous Polyposis (FAP)
REC-4881-201 A PHASE 2, MULTICENTER, TRIAL TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF REC-4881 IN PATIENTS WITH FAMILIAL ADENOMATOUS POLYPOSIS (FAP)
Principal Investigator: Gautam Mankaney, MD
Status: Enrolling- Gastroparesis
Examination of Programming with the Enterra® Therapy System in a Double-Blinded, randomized, Prospective Study In the Treatment of Nausea and Vomiting Symptoms using Gastric Electrical Stimulation
Principal Investigator: Pierre Blais, MD
Status: Enrolling- Non Alcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Subjects with Compensated Cirrhosis due to NASH
Principal Investigator: Asma Siddique, MD
Status: Closed to Enrollment- Stricture
Paclitaxel Coated balloon for the Treatment of chronic bEnigN sTricture- Bowel
Principal Investigator: Joanna Law, MD
Status: Enrolling- Ulcerative Colitis
A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults with Mild to Moderate Ulcerative Colitis
Principal Investigator: Tim Zisman, MD
Status: EnrollingCasting Light on Urgency and Effectiveness of Advanced Therapies in Ulcerative Colitis (CLUES-UC): A Non-interventional, Observational Cohort Study of Mirikizumab and Other Biologics in Adult Participants with Moderately to Severely Active Ulcerative Colitis
Principal Investigator: Tim Zisman, MD
Status: EnrollingA Multicenter, Randomized, Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065
Principal Investigator: Tim Zisman, MD
Status: Closed to EnrollmentA Phase 2b Randomized, Double-blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colitis
Principal Investigator: Tim Zisman, MD
Status: Closed to EnrollmentA Phase 3 Multicenter, Open-Label Extension (OLE) Study to Evaluate the Long-Term Safety and Efficacy of ABT-494 in Subjects with Ulcerative Colitis (UC)
Principal Investigator: Tim Zisman, MD
Status: Closed to Enrollment